WCLC Expert Commentary: Dr. Nan Bi Discusses the LAURA Study Results and the Challenges of EGFR-Positive LA-NSCLC Targeted Consolidation Therapy

WCLC Expert Commentary: Dr. Nan Bi Discusses the LAURA Study Results and the Challenges of EGFR-Positive LA-NSCLC Targeted Consolidation Therapy

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently underway in San Diego, USA. Oncology Frontier has invited leading Chinese lung cancer experts to analyze the key research data from this conference. This article highlights Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, as she shares her thoughts on the LAURA study results (Abstract No. OA12.03).
WCLC China Special Session: Exploring Global Lung Cancer Prevention and Evidence-Based Medicine

WCLC China Special Session: Exploring Global Lung Cancer Prevention and Evidence-Based Medicine

At the 2024 World Conference on Lung Cancer (WCLC), the International Association for the Study of Lung Cancer (IASLC), the Chinese Society of Clinical Oncology (CSCO), and the Chinese Alliance Against Lung Cancer (CAALC) came together once again to host a joint session. Held on Saturday, September 7, from 8:00 AM to 12:00 PM, the session focused on the development and future prospects of evidence-based medicine in lung cancer prevention worldwide. The session was chaired by IASLC President-Elect, Dr. Caizun Zhou from Shanghai East Hospital, alongside Dr. Yilong Wu from Guangdong Provincial People's Hospital, IASLC CEO Dr. Karen Kelly, and Dr. Chunxue Bai from Fudan University’s Zhongshan Hospital.
Dr.Yuankai Shi: INTELLECT Study Reveals mOS of 41.8 Months, Offering Prolonged Survival for NSCLC Patients Resistant to Crizotinib

Dr.Yuankai Shi: INTELLECT Study Reveals mOS of 41.8 Months, Offering Prolonged Survival for NSCLC Patients Resistant to Crizotinib

The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) was held in San Diego, CA USA on September 7th. The mOS data from the INTELLECT study was disclosed at the conference on September 8th. Oncology Frontier has invited the lead principal investigator of the INTELLECT study, Dr. Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences, to share the latest findings from this groundbreaking research reported at the WCLC. This study highlights the promising outcomes of Iruplinakib treatment for advanced NSCLC patients resistant to crizotinib.
WCLC 2024 | Dr. Patel Discusses the Anticipation for IASLC’s 50th Anniversary Celebration

WCLC 2024 | Dr. Patel Discusses the Anticipation for IASLC’s 50th Anniversary Celebration

The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). This milestone celebration will feature unique activities commemorating IASLC’s rich history, under the theme "Across the Decades." The event will be held on September 8 in San Diego’s famous Gaslamp Quarter, where attendees can enjoy local cuisine, dance, and commemorative attire throughout the evening.
Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Recently, Professor Xiaofan Zhu, Director of the Division of Pediatric Hematology and Oncology Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Associate Chief Physician Doctor Min Ruan and Attending Doctor LiPeng Liu collaborated on a study titled "Early Detection of Minimal Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA," published in Clinical Cancer Research (with an impact factor of 11.5). This prospective study was the first to evaluate the longitudinal changes of ctDNA from plasma in patients, as compared to NGS based bone marrow DNA, for the early detection of relapse in children with AML.
Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

Frontiers in Gynecologic Oncology | Can Severe Endometriosis Significantly Increase the Risk of Ovarian Cancer?

A large population-based cohort study led by Dr. Mollie E. Barnard from the Huntsman Cancer Institute at the University of Utah has found that women with endometriosis have an overall higher risk of ovarian cancer, with the risk being significantly elevated in those with severe types of endometriosis. This study, published in the journal of the American Medical Association [1], suggests that these women may benefit from counseling on ovarian cancer risk and prevention, as well as potential ovarian cancer screening.